

7th August, 2017

BSE Limited
Corporate Relations Department
P J Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 532300

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051
NSE Symbol: WOCKPHARMA

Dear Sirs/ Madam,

Sub Press Release

Please find enclosed herewith proposed Press Release titled "Wockhardt Receives US FDA Approval for Antibiotic Injection."

Kindly take the same on records please.

Thanking you,

for **Wockhardt Limited**



Narendra Singh
Company Secretary

Encl: Press Release



PRESS RELEASE

WOCKHARDT

**LIFE
WINS**

Wockhardt Limited
D-4, MIDC, Chikalthana
Aurangabad
Maharashtra 431 006 India
Tel.: +91-22-2653 4444
www.ockhardt.com

Mumbai, August 7, 2017

Wockhardt Receives US FDA Approval for Antibiotic Injection

Pharmaceutical and biotechnology major Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 1gm, and 2gm injections of Oxacillin.

Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as Urinary Tract Infections, Respiratory Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc.

Wockhardt is expected to launch this product in the United States, soon. The product is being manufactured at a contract manufacturing facility, based near Milan, Italy.

About Wockhardt Limited

Wockhardt is a Global Pharmaceutical and Biotech company employing over 10,000 people and 27 nationalities with presence in USA, UK, Ireland, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 66% of its global revenues coming from international businesses. Wockhardt is home to 600 plus scientists, of whom 70 plus are doctorates. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive. Wockhardt's entire Anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed.